Evidence map›Paper›PMID 29467399›Full record

ArticleScientific reports2018

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.

Carly M Bliss, Georgina Bowyer, Nicholas A Anagnostou, Tom Havelock, Claudia M Snudden, Huw Davies, Simone C de Cassan, Amy Grobbelaar, Alison M Lawrie, Navin Venkatraman and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

  1. Protein/AS01Cell reports. Medicine · 2021
    Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Targeting Antigen to the Surface of EVs Improves theMolecular therapy. Methods & clinical development · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Carly M BlissThe Jenner Institute, University of Oxford, Oxford, UK. carly.bliss@ndm.ox.ac.uk.ORCID 0000-0002-5117-1016
Georgina BowyerThe Jenner Institute, University of Oxford, Oxford, UK.ORCID 0000-0002-2058-4045
Nicholas A AnagnostouThe Jenner Institute, University of Oxford, Oxford, UK.
Tom HavelockNIHR Wellcome Trust Clinical Research Facility, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Claudia M SnuddenThe Jenner Institute, University of Oxford, Oxford, UK.
Huw DaviesDepartment of Medicine, Division of Infectious Diseases, University of California, Irvine, CA, USA.
Simone C de CassanThe Jenner Institute, University of Oxford, Oxford, UK.
Amy GrobbelaarThe Jenner Institute, University of Oxford, Oxford, UK.
Alison M LawrieThe Jenner Institute, University of Oxford, Oxford, UK.
Navin VenkatramanThe Jenner Institute, University of Oxford, Oxford, UK.
Ian D PoultonThe Jenner Institute, University of Oxford, Oxford, UK.
Rachel RobertsThe Jenner Institute, University of Oxford, Oxford, UK.
Pooja B MangeThe Jenner Institute, University of Oxford, Oxford, UK.
Prateek ChoudharyThe Jenner Institute, University of Oxford, Oxford, UK.
Saul N FaustNIHR Wellcome Trust Clinical Research Facility, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Stefano CollocaReiThera (formerly Okairos), 00144, Rome, Italy.
Sarah C GilbertThe Jenner Institute, University of Oxford, Oxford, UK.ORCID 0000-0002-6823-9750
Alfredo NicosiaReiThera (formerly Okairos), 00144, Rome, Italy.
Adrian V S HillThe Jenner Institute, University of Oxford, Oxford, UK.ORCID 0000-0003-0900-9629
Katie J EwerThe Jenner Institute, University of Oxford, Oxford, UK.ORCID 0000-0001-9827-9836
University of Oxford · GBUniversity Hospital Southampton NHS Foundation Trust · GBCeinge Biotecnologie Avanzate (Italy) · ITUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heterologous prime-boost vaccination with viral vectors simian adenovirus 63 (ChAd63) and Modified Vaccinia Ankara (MVA) induces potent T cell and antibody responses in humans. The 8-week regimen demonstrates significant efficacy against malaria when expressing the pre-erythrocytic malaria antigen Thrombospondin-Related Adhesion Protein fused to a multiple epitope string (ME-TRAP). We tested these vaccines in 7 new 4- and 8- week interval schedules to evaluate safety and immunogenicity of multiple ChAd63 ME-TRAP priming vaccinations (denoted A), multiple MVA ME-TRAP boosts (denoted M) and alternating vectors. All regimens exhibited acceptable reactogenicity and CD8

Indexed as

Adenoviruses, SimianAdolescentAdultAntibodies, ProtozoanAntigens, ProtozoanCD8-Positive T-LymphocytesEpitopesFemaleGenetic VectorsHumansImmunization, SecondaryLiverMalaria, FalciparumMalaria VaccinesMaleMiddle AgedAntibodies, ProtozoanAntigens, ProtozoanEpitopesMalaria VaccinesProtozoan Proteins

Identifiers

PMID29467399
PMCPMC5821890
OpenAlexW2806922905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.